Recent preclinical and clinical studies indicate that irradiation using ionizing radiation in the dose range of 15 to 30 Gy may reduce the occurrence of restenosis in patients who have undergone an angioplasty. Several delivery systems of intravascular brachytherapy have been developed to deliver radiation doses in this range with minimal normal tissue toxicity. In late 1995 the American Association of Physicists in Medicine ͑AAPM͒ formed a task group to investigate these issues and to report the current state of the art of intravascular brachytherapy physics. The report of this task group is presented here.
I. INTRODUCTION
Coronary artery disease is the leading cause of morbidity and mortality in the western world. 1 Approximately 450 000 angioplasties are performed annually in the USA. Although major complications from angioplasty occur in only 1%-2% of patients, angiographically diagnosed restenosis occurs in 35%-40% of patients. 2 Restenosis is the major limitation of angioplasty. The impact of restenosis is highlighted by studies that compared coronary angioplasty to bypass surgery as a treatment strategy for coronary artery disease. Patients treated by angioplasty had lower initial costs and fewer major complications, but at a six month to three year follow-up these patients had more angina, required more revascularization procedures, and most of the cost benefit of angioplasty was lost because of restenosis. 3 Coronary stent placement in conjunction with angioplasty can reduce the restenosis rate to 22%-32%. 4, 5 The cost of restenosis has been estimated to be $4000-$7000 in direct costs for the first episode of restenosis. The societal cost of restenosis in the United States of America is estimated between 800 and 2000 million dollars per year. 2 Recent preclinical studies indicate that irradiation using ionizing radiations in the dose range of 15-30 Gy may reduce substantially the problem of restenosis in patients who have undergone an angioplasty. Using intravascular brachytherapy, radiation doses in this range can be delivered with minimal normal tissue toxicity because of the high localization of dose to the immediate vicinity of radioactive sources in brachytherapy. It is estimated that the restenosis rate may drop from roughly 35%-40% to well below 10% if radiation is delivered to the obstruction site during or after angioplasty. 6 Therefore, the potential of intravascular brachytherapy in reducing restenosis has aroused a tremendous interest in the cardiology community.
Dosimetry at distances of the order of a millimeter from radioactive sources is poorly known. In traditional brachytherapy the dose is typically specified at 1 cm from the source and effects of low-energy photons and secondary electrons are essentially ignored. In intravascular brachytherapy, however, the entire lesion may be 1-3 mm in thickness. To understand the results of various preclinical studies using a variety of radionuclides and delivery systems, it is essential to determine the dosimetry in the millimeter range. A better understanding of dosimetry in the millimeter range will help in the development of optimum clinical devices and their efficacious use in different institutions using different radionuclides and devices.
In late 1995 the American Association of Physicists in Medicine ͑AAPM͒ formed a task group to investigate these issues and report the current state of the art of intravascular brachytherapy physics. The specific charge to the task group included the following:
͑1͒ To review the physical, radiobiological, and clinical rationale of using intravascular brachytherapy. ͑2͒ To review the currently proposed irradiation techniques:
͑a͒ intravascular gamma radiation ͑e.g.,
192
Ir) brachytherapy; ͑b͒ intravascular beta radiation ͑e.g., 33 P) brachytherapy. ͑3͒ To review the literature for types and applications of various interventional probes, including specifically the use of intra-arterial stents. ͑4͒ To review the interventional diagnostic imaging procedures including intravascular ultrasound used in evaluation and treatment planning for brachytherapy. ͑5͒ To recommend a dose prescription site ͑or region͒ for selected intravascular brachytherapy procedures ͑e.g., 1 mm depth from the arterial lumen surface or 2 mm from the center of the lumen, etc.͒. ͑6͒ To recommend calibration and dosimetry procedures ͑relative and/or absolute͒ for the determination of dose distributions around intravascular brachytherapy applicators, including beta-emitting stents. ͑7͒ To recommend a quality assurance procedure, including radiation safety, for the safe and efficacious application of intravascular brachytherapy.
Here we present the recommendations of the AAPM on the physics of this novel application of radiation in the treatment of cardiovascular disease.
II. CLINICAL BACKGROUND AND RATIONALE

A. Overview of coronary anatomy
The arteries conduct blood from the heart to the capillary bed in the heart muscle. The arterial system begins in large blood vessels close to the heart. The largest, the aorta, carriers the full volume of blood expelled and is approximately 2-3 cm in diameter. The division of this and subsequent major branches leads to a continuous increase in their number and spread, with a progressive decrease in their diameter.
The coronary arteries are a branching system of mildly to severely tortuous vessels lying on the outer surface of the heart. Two main coronary arteries, the left and right coronary arteries ͑LCA and RCA͒, originate from the aortic root, just outside the aortic valve. The branching of these main arteries, and the regions of the heart they serve, vary considerably among individuals, although there are some general patterns ͑Fig. 1͒. The RCA, which serves the inferior wall of the left ventricle and portions of the right ventricle, has few branches in the proximal half of its length. The LCA bifurcates within a few centimeters of its origin into the left anterior descending ͑LAD͒ and left circumflex ͑LCX͒ arteries, both of which give rise to many tertiary branches.
Normal proximal coronary arteries range from 3-5 mm diam at their origin and taper slowly throughout their length, except at major bifurcations, where the sum of the branch cross-sectional areas is approximately equal to the area proximal to the bifurcation. Angioplasty is rarely performed in arteries with a normal diameter less than about 1.5 mm, and, at present, stents are rarely placed in arteries whose normal diameter is smaller than about 3.0 mm, as measured by angiography.
Arteries consist of a tubelike structure that is lined by endothelium ͑Fig. 2͒. Next to the endothelial layer is a subendothelial connective tissue layer called the intima, which has surface cells flattened and longitudinally oriented. Intima is surrounded by an elastic layer called the internal elastic membrane. Surrounding these inner layers is a relatively thick layer of media composed of smooth muscle cells and elastic tissues in varying proportions. The outer layer of the media is called the external elastic membrane. The outermost layer of arteries is the adventitia, composed mainly of collagenous fiber. The principal difference between arteries of different sizes is found in the media. In larger vessels elastic tissue predominates, while in the smaller vessels smooth muscle cells form most of the substance.
B. Atherosclerosis and restenosis
Atherosclerosis is the formation of plaques that gradually reduce the lumen of the artery, compromising blood flow and oxygen delivery. The plaque begins in the intima by deposits of fatty debris from blood. Smooth muscle cells from the internal elastic membrane and media proliferate. Collagen and elastin are produced and accumulate in the intima, leading to focal thickening where platelets and cholesterol soon begin to adhere to the endothelium ͑Fig. 2͒. As the disease progresses, lipids accumulate in the intima to form yellow fatty streaks. A fibrous plaque then begins to form. It contains lipids, necrotic cells, and collagen. The media becomes thickened from this process. Eventually, a complex lesion develops as the core of the fibrous atherosclerotic plaque necroses, calcifies, and hemorrhages. This causes reduction in blood flow, platelet aggregation, and ultimately formation of a thrombosis with consequent myocardial ischemia and/or infarction.
Restenosis after an angioplasty follows a similar history. 7 Angioplasty leads to a fracture of the atherosclerotic plaque, the intima, and sometimes extending into the media ͑Fig. 2͒. These injury sites are immediately lined by platelets and later lined by a fibrin meshwork in which platelets and red blood cells become entrapped. This thrombus usually stabilizes over the course of minutes to hours. Within several days blood borne monocytes initiate the phagocytosis of the fibrin meshwork. Simultaneously smooth muscle cells migrate from the media into the intimal subendothelial space, leading to neointimal proliferation. Over weeks to months the neointima becomes less cellular and the healing site begins to resemble a fibrous plaque. In most patients the lumenenlarging effect of angioplasty outweighs the lumennarrowing effect of neointimal hyperplasia. However, in about 40% of the patients neointimal hyperplasia is excessive and results in clinically symptomatic restenosis within three to six months. Since the 1950s the gold standard for the diagnosis of coronary atherosclerosis has been the angiogram. The utility of the angiogram derives from its ability to determine easily the distribution of coronary arteries and the location of atherosclerotic narrowings. However, the angiogram is not able to image the atherosclerotic plaque itself. The development of intravascular ultrasound ͑IVUS͒ has led to a new tool capable of imaging the distribution of plaque, the calcium deposits in the plaque, and the placement of the stent. [8] [9] [10] [11] A typical example of IVUS images is illustrated in Fig. 3 from a recent review by Yock et al. 12 Such cross-sectional views of the vessel anatomy have proven useful in treatment planning of intravascular brachytherapy.
C. Percutaneous transluminal angioplasty
The primary objective of angioplasty is to re-establish a stable lumen with a diameter similar to that of the normal artery. This goal may be achieved using a variety of interventional devices, including the angioplasty balloon, laser, rotoblator, and stent, all described briefly below. The selection of one or more interventional devices for a given stenotic lesion depends on the size, location, and characteristics of the lesion. A brief review of these devices is presented now.
Balloons: in cases where the lesion can be spanned with an angioplasty balloon, a sufficient increase in diameter ͑''acute gain''͒ can often be achieved by balloon dilatation alone. The mechanism by which balloon angioplasty increases lumen diameter is by stretching and usually rupturing the internal elastic lamina, often resulting in one or more fissures extending into the medial layer. Flaps may protrude into the lumen, and/or a dissection may extend well beyond the angioplasty site. These common post-angiographic morphologies increase the risk of thrombosis and abrupt occlusion. In addition to this source of acute failure, the most important problem is restenosis.
Cutting and ablating devices: while balloon angioplasty enlarges the lumen by stretching and splitting the wall, in some cases this is made impossible by lesions with a lumen too small for the balloon to cross, or by heavy calcification of the arterial wall, making it too tough and inelastic to split or stretch. In these cases it may be necessary to remove tissue by cutting ͑atherectomy device͒, abrading ͑rotoblator͒, or vaporizing ͑laser͒. Because the risk of arterial wall perforation is clearly much higher with these methods, they are usually not applied aggressively to achieve the desired final lumen size; rather, they are used to initially ''debulk'' the lesion, and then followed by balloon angioplasty and/or stent placement.
Stents: placement of one or more intra-arterial stents following angioplasty effectively repairs dissections, prevents flaps from protruding into the lumen, resists elastic recoil, and minimizes loss of lumen diameter due to remodelling, significantly improving the short term result of angioplasty. For this reason stents are being placed in an increasing fraction of angioplasty procedures. However, stents do not appear to eliminate restenosis and, in fact, may actually stimulate proliferation. For this reason there is a strong interest in finding a method, such as radiation therapy, that can be used in conjunction with stenting to produce a definitive intervention for obstructive atherosclerotic lesions.
D. Overview of the restenosis problem
Restenosis is a complex process comprising three separate mechanisms: early recoil, neointimal hyperplasia, and late contraction ͑Fig. 4͒. 13 Chronologically, the first is the elastic recoil that occurs promptly after the overstretch of the artery. This has been quantitated at approximately 50% of the crosssectional area or one-third the lumen diameter on average. In other words, an artery dilated with a 3 mm balloon will commonly have a lumen in the dilated segment of 2 mm following balloon deflation and passage of a few minutes time. This elastic recoil does not seem to progress much beyond the first few minutes after balloon deflation. Observations made the day following balloon angioplasty show little further decrease in lumen size. The second component of restenosis is intimal proliferation resulting in new tissue growth occupying the cracks and tears in the vessel wall and sometimes growing to produce very severe reobstruction of the artery. This process probably begins within days after angioplasty and continues for weeks or months. The third mechanism for restenosis that has been recently elucidated is analogous to wound contracture and is sometimes called remodeling. The entire artery may become contracted so that the external elastic lamina occupies a smaller circumference than it did following the procedure. It has been estimated by Mintz 14 that this process may account for up to 60%-65% of the lumen loss judged by intravascular ultrasound.
Although the focus of the discussion above has been coronary arteries, similar problems of restenosis following angioplasty or stent placement have been encountered within the peripheral vascular system. Several institutions report fiveyear patency rates following femoropopliteal balloon angioplasty of 50%-61%. Recent studies of stents in femoropopliteal vessels demonstrated a similarly high rate of restenosis as with balloon angioplasty. [15] [16] [17] [18] [19] This phenomenon seems less frequent in stented iliac and renal arteries. The incidence of restenosis in peripheral vessels seems highly dependent on the anatomic location of the original lesion, the morphology of the lesion, and the distal flow with lower restenosis rates occurring in larger vessels, and focal lesions with good distal flow.
E. Preclinical studies of vascular irradiation
The potential role of radiation in preventing restenosis following angioplasty or stent placement was first elaborated in the literature by Dawson, 20 although there exists clinical and preclinical studies antedating this publication. The first author to report the use of endovascular brachytherapy was Friedman and his group 21 from the Mount Zion Hospital in San Francisco, who in the mid 1960s showed that the formation of vascular plaques could be inhibited by inserting an 192 Ir wire into the aorta and delivering approximately 14.4 Gy to the vessel wall. It remained until the early 1990s when several investigators reported mixed results using external beam radiotherapy. [22] [23] [24] [25] [26] [27] [28] Interest in intravascular brachytherapy grew recently when groups led by Weinberger from Columbia, Waksman from Emory, and Raizner from Baylor reported a potential benefit of intraluminal 192 Ir in the prevention of restenosis in the porcine model. In the Columbia and Emory studies the radiation was administered with a hand delivered 192 Ir ribbon ͑Best Industries, Springfield, VA͒. Raizner delivered the dose in their study with a high dose rate afterloader ͑Omni-tron, Houston, TX͒. Comparing their results is confounded by differences in source configuration and prescription points, and methods of analysis. Weinberger [29] [30] [31] found that 15 and 20 Gy delivered at a 1.5 mm distance from the source center significantly reduced neointimal hyperplasia, but 10 Gy was worse than controls. In contrast, Waksman et al. 32, 33 showed that doses in the range of 3.5-14 Gy delivered at a 2 mm distance from the source center ͑0.5 mm depth from a typical arterial wall͒ significantly reduced neointima formation compared to controls with the animals being sacrificed at two weeks following injury. Here 14 Gy was associated with the greatest reduction in neointima formation and 7 Gy when administered 48 h following balloon injury was more effective than when delivered at the time of injury. Mazur 34 examined the potential benefit of 10, 15, and 25 Gy delivered at 1.5 mm depth and found that 15 and 25 Gy were effective, but no benefit was seen with 10 Gy. Both Waksman and Weinberger subsequently extended these observations to six months and showed the durability of this effect. In these studies Waksman et al. showed the benefit of delivering 7 and 14 Gy at 2 mm depth and Weinberger's group showed a durable effect with 20 Gy at 1.5 mm depth at six months.
Two groups reported on preclinical studies utilizing beta sources developed specifically for clinical use. Verin 35, 36 has shown in a hypercholesterolemic rabbit restenosis model that radiation delivered with a 90 Y wire would reduce neointimal hyperplasia. In their study doses of 6, 12, and 18 Gy were delivered at the intimal surface immediately following balloon angioplasty and the animals were sacrificed six weeks later. Although BUdR labeling was reduced at eight days with 6, 12, and 18 Gy, only the 18 Gy group showed a significant reduction of neointima formation at the six-week period. Waksman et al. 37 reported two studies with a ribbon of 90 Sr/Y seeds. When used following balloon angioplasty in the porcine model of restenosis, there was a significant reduction in neointimal hyperplasia with doses of 7, 14, 28, and 56 Gy delivered to a 2 mm distance from the center of the source. There was evidence of a dose response curve with maximal reduction in neointima seen at 28 Gy. When they compared their results obtained with the beta source and
192
Ir there was no difference between them in terms of efficacy. The treatment times and radiation exposures to animals and personnel were significantly reduced with the beta source. A second publication from this group also showed that radiation delivered prior to stent implantation with either 192 Ir or 90 Sr/Y was effective in reducing neointimal hyperplasia compared with stents alone.
Two groups reported using radioactive stents as a means of preventing restenosis. Hehrlein 38 was the first to demonstrate that a regular metallic stent ͑Palmaz-Schatz͒ made radioactive in a cyclotron could reduce restenosis when applied to rabbit iliac vessels. A stepwise reduction of neointimal hyperplasia was seen with stent activities between 3.9 and 35 Ci. Although there was evidence of delayed reendothelialization, no increase in vascular thrombosis was seen. Laird et al. 39 has reported that neointimal hyperplasia could be inhibited in the short term by the application of a 32 P impregnated stent. These stents had activities in the range of 0.14 Ci and delivered doses to tissue of approximately 280 cGy ͑a more detailed analysis of dosimetry is discussed later in Sec. VII C and Table VI͒ . When assessed at 28 days post-implantation, there was a significant reduction in neointimal proliferation and stenosis with the radioactive stents. There would seem to be some advantage to the 32 P impregnated stent over the radioactive steel stent due to the long half-life of some of the decay products of the steel stent. Sources with activities described by these authors could be handled without significant radiation precautions unlike the catheter-based systems.
F. Clinical studies of vascular irradiation
Peripheral vessels
The first study done using radiation to prevent restenosis was carried out by Liermann, Schopohl, and Bottcher in Frankfurt. 40, 41 In this study they selected patients for treatment who had a clinically relevant recurrent stenosis in the superficial femoral artery greater than 4 cm in length that had occurred less than six months after the last percutaneous transluminal angioplasty ͑PTA͒. All the patients had undergone prior PTA or laser therapy and had a stent placed prior to or at the time of irradiation, and all patients were 65 years or older. The patients received 12 Gy at the lumenal surface with a HDR afterloader. With 25 patients treated as of their latest follow-up report and some patients with over five years of follow-up, they have not seen any evidence of restenosis in the treated segment. Not all of the patients have undergone systematic reevaluation with angiography so there is no information published or presented at this time as to any degree of lumenal narrowing following treatment. One would have generally expected at least a 30% restenosis rate in these size vessels following primary angioplasty, and this study provides strong evidence for the benefit of adjuvant irradiation. What is more important, however, is the fact that there was no late restenosis or other evidence of complications of the adjuvant irradiation. The authors point out in their paper that the source was not centered within the peripheral vessel, and if the catheter had remained opposed to one of the coronary arteries for the duration of the treatment it is possible that the absorbed dose, based on minimum and maximum distances of the vessel wall, ranged from Gy. This information gives us some indication that the dose range of effective treatment and safety could be quite broad.
The second clinical study of irradiation in peripheral vessels was also carried out in Germany by Steidle 42 and his colleagues in Ravensburg. This study was a randomized study between stent placement with and without adjuvant, fractionated external radiation treatment. The patients were treated with 12.5 Gy in 2.5 Gy fractions following stent placement in superficial femoral arteries. Of the 11 patients who received radiation treatment, there were only two episodes of occlusion with minimum seven months follow-up. In the 13 control patients there were five episodes of occlusion. Furthermore, there were no complications attributable to the radiation.
The only additional study carried out in peripheral vessels in humans is a preliminary report from Waksman et al. 43 involving adjuvant irradiation following angioplasty at the venous anastamotic stenosis in percutaneous grafts in dialysis patients. Stenosis at the venous anastamosis of the polytetrafluoroethylene ͑PTFE͒ graft with the outflow vein is the most common ͑Ϯ80%͒ underlying cause of graft failure. Patency rates after recanalization with thrombolysis and angiolasty are plagued by recurrent restenosis: six months patency rates are only 30%-45%. In the 11 patients ͑16 lesions͒ treated at Emory with radiation following angioplasty, only 36% of the grafts remained patent at 44 weeks. This pilot study was too small to determine effectiveness of radiation and did not use a centering catheter for the wire, a probable requirement for dose optimization.
A randomized multicenter trial for intravascular brachytherapy of femoral popliteal arteries has been initiated by Waksman. This protocol is approved by the USFDA. In this protocol the irradiated group will receive 14 Gy to a depth of 2 mm from the vessel wall. The intent is to deliver this dose to the adventitia using a centered catheter-based beta source. Nori et al. have initiated a phase I/II FDA approved pilot study using external beam irradiation therapy following angioplasty of venous outflow stenosis in failing grafts.
Coronary vessels
The first study of intracoronary brachytherapy in humans was initiated in July 1994 by Condado and his colleagues in Caracas, Venezuela. 44 This study involved the administration of radiation from the insertion of a special small diameter 192 Ir wire ͑1.5 Ci͒ into the vessel after angioplasty, rotoblator, or stent placement. In this study 22 arteries in 21 patients were treated over a five-month period of time. At the initiation of their study, the patients received 25 Gy at a standard depth of 1.5 mm from the source center. After the first ten arteries were treated, a further 12 arteries were treated with all but one of these patients receiving 20 Gy at the lumenal surface of the reference diameter. With a minimum of six months follow-up in the treatment groups there have been four cases of restenosis. Angioplasty was successful in 20 of 22 lesions. The delivery of radioactive source wire was successful to all treated sites and was free of major procedural complications. Angiographic study at 24 h post-procedure Ir group versus 54% of those in the placebo group. What is more important about this trial is the fact that they have managed to use a hand-delivered iridium source of up to ϳ140 mCi without seeing any increase in badge readings of the participating physicians. Furthermore, they have left the radiation source within the coronary artery for up to one-half hour without any increase in complications from this procedure. Results of this randomized trial indicate that radiotherapy and stenting significantly reduced subsequent restenosis in patients with previous restenosis; restenosis was decreased by angiographic, ultrasonographic, and clinical measurements; and no adverse events were observed at about 12 months. The investigators conclude that radiotherapy with 192 Ir reduces the proliferative response to human coronary angioplasty.
Intraluminal beta irradiation has been shown by Popowski et al. 46 to markedly decrease fibrointimal proliferation after PTCA. Between June 21 and November 15, 1995, 15 patients ͑six women and nine men, age 72Ϯ5 years͒ underwent intracoronary beta irradiation immediately after a conventional PTCA procedure. Both the PTCA and irradiation procedure were done in a conventional catheterization laboratory, using an endoluminally centered pure metallic 90 Y source, a newly developed technique of intracoronary beta irradiation. Both the PTCA and the irradiation procedure were technically feasible in all attempted cases, and a dose of 18 Gy was delivered, with a local exposure time of 400 Ϯ200 s ͑the range 153-768 s͒. In four patients the intervention was completed by intra-arterial stent implantation because of dissection induced by the initial PTCA. These early experiences of Popowski et al. suggest that reliable and reproducible dose delivery can be achieved, and that coronary endoluminally centered beta brachytherapy is both feasible and safe on a short-term basis in the clinical setting.
King et al. 47 initiated a feasibility trial using a catheter system based on a 90 Sr/ 90 Y beta source. At present, 23 patients have undergone balloon angioplasty followed by endovascular irradiation. The 30-day safety endpoint examination has been completed without any adverse events being noted, and the patients are being followed with angiographic examinations at six months to document the degree of neointimal formation, the late lumen loss and loss index, the restenosis rate, and any other effects that might be observed angiographically. Although there is no control group for this study, the patients were selected by the criteria of the Lovastatin™ restenosis trial and the quantitative angiographic assessment is being performed by the same core laboratory that performed that trial. Early results from this feasibility study are also highly encouraging.
Early clinical trials with 32 P stent activities of 0.5-3.0 Ci have shown no untoward events at 1 month follow-up. 48 Presently, clinical dose escalation safety studies using 32 P Palmaz-Schatz stents are underway in the USA and Europe; additionally planned randomized clinical trials are forthcoming.
III. IRRADIATION TECHNIQUES
Intravascular brachytherapy techniques fall naturally into two categories: ͑1͒ temporary implant-balloon angioplasty ͑radioactive seed or wire͒ and ͑2͒ permanent implantradioactive stent. For temporary implants, single fraction, acute doses of [15] [16] [17] [18] [19] [20] Gy are required to a length of 2-3 cm of the vessel wall, which may be 2-5 mm in diameter. The dose distribution should be confined to the region of the angioplasty, with reduced doses to normal vessels and the myocardia. Dose rates greater than 5 Gy/min would be optimal in order to maintain treatment times within tolerable limits, although precise requirements are not yet known. Depending on catheter design, the patient will have greatly reduced arterial blood flow during irradiation, and longer treatment times will increase the risk of complications. This suggests high dose rate ͑HDR͒ afterloading, perhaps with specially designed sources suitable for insertion into standard or modified catheters.
Current angiographic techniques utilize open ended catheters flexible enough to negotiate multiple bends between the femoral and coronary arteries, yet stiff enough to be pushed through greater than 100 cm of the artery. Vessels suitable for intravascular brachytherapy may be as small as 3 mm diam and small radii of curvature need be navigated. The radioactive source must have similar flexibility. Source integrity is of great importance as dislodgment into a coronary artery could be fatal. Seeds should have dimensions on the order of less than or equal to 1 mm diam and 1-10 mm length. Treatment with such a source would require either multiple sources on a line ͑such as those currently available for conventional afterloading͒, or programmable source placement ͑similar to conventional HDR units͒ to permit treatment of 2-3 cm of coronary artery wall, or up to 5 cm of the vessel wall in peripheral vessels. In theory, the source could be inserted directly into the coronary artery, or, more likely, into a conventional or slightly modified balloon catheter. In either case, it is desirable that the source be centered within the coronary artery to ensure uniform dose to the arterial walls. Balloon catheters designed to ensure some centering have recently been developed by some manufacturers.
The objective of intravascular brachytherapy is to irradiate a lesion with a size of millimeters in contrast to conventional brachytherapy, where the lesion may be 1-5 cm in size. This makes it possible to consider low-energy photon emitters and beta emitters as potential sources for intravascular brachytherapy. For conventional interstitial brachytherapy procedures such as those for prostate cancer photon energies as low as of 20-30 keV are considered adequate. However, for conventional intracavitary brachytherapy, such as those for gynecological cancers, it is necessary to use a minimum photon energy of about 50 keV in order to obtain adequate depth of penetration. 49 For the same reason, i.e., the inadequate depth of penetration in tissue, the beta emitters are generally not suitable for conventional brachytherapy. Nath and Liu 50 explored this issue of intravascular brachytherapy by calculating radial dose functions of a range of energies for photons and electrons in the range of 1-10 mm using Monte Carlo simulation. Calculated radial dose functions for photons and electrons in a point source geometry are shown in Fig. 5 . The reference depth was chosen to be 2 mm. It was concluded that photons above an energy of 20 keV and electrons above an energy of 1.0 MeV are acceptable from the point of view of an adequate depth of penetration for intravascular brachytherapy.
Many different radionuclides 51 are under investigation for intravascular brachytherapy ͑Table I͒. Most intravascular brachytherapy studies to date have used 192 Ir seeds of 10-20 mCi activity. Typical seed dimensions are 0.5 mm diam, 3 mm in length. Multiple seed arrays embedded in a 1 mm diam plastic catheter are used with variable spacing but usually less than or equal to 0.5 cm. While these sources have proven useful for preliminary studies, the relatively highenergy and low dose rates are not ideal. In addition, to achieve the dose rates of 4-5 Gy/m, approximately 500-1000 mCi of gamma emitting isotopes will be required. This will present additional radiation safety problems, with either HDR or hand loaded sources. Lower-energy gamma and x-ray emitters such as 125 I and 103 Pd also present fewer radiation safety problems, but are not currently available at the required specific activities. 32 P, 90 Sr, 90 Y, and other beta emitters have been suggested. Beta emitters would require much lower total activities ͑20-50 mCi͒ and have additional, obvious radiation safety advantages. Electrons from some common beta emitters, however, may not have sufficient range for treating larger diameter peripheral vessels.
An alternative possibility for irradiation is to inject a betaemitting liquid directly into the angioplasty balloon. This may have advantages over other proposed procedures in that accurate source positioning and uniform dose to the vessel walls is assured, and it can be used in conjunction with existing catheters. About 370 MBq ͑equal to 10 mCi͒ of 32 P in a 0.2 ml balloon would be required to deliver 20 Gy at a distance of 2 mm from the center. The chemical and radiological toxicity must also be acceptable, in the event of balloon rupture ͑the probability of balloon rupture is less than 0.001͒. Several high-energy beta-minus emitters ͑and possibly positron emitters͒ appear to be possible for this application.
Beta-minus emitters, such as Pd may also be possible. The radioactive material can be coated onto, or impregnated into, the actual stent using ion implantation techniques. Activation of the stent in a nuclear reactor is also possible. The advantages of radioactive stent implantation include conformity of dose to the lesion and very low activities ͑Ci͒.
For any of these techniques, cost and half-life will be factors in source selection. If the amortized cost of the radioactive source is greater than $10 3 -$10 4 per patient, the treatment may not be economically viable. A high demand for these treatments, however, can reduce substantially the cost per patient. The remote-controlled afterloaders may have a higher capital cost but lower operational cost compared to radioactive stents.
IV. OVERVIEW OF BASIC PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY "PTCA… PROCEDURES AND DEVICES
Reliable systems have evolved for establishing arterial access, controlling bleeding, and maneuvering catheters and catheter-based devices through the arterial tree to the treatment site. Systems for peripheral and coronary arteries are similar, but the smaller size and greater tortuosity of the coronaries require smaller and more flexible devices. Detailed descriptions of these systems exist in textbooks as well as in device manufacturers' literature. Here we present an overview of typical systems for coronary angiography, balloon angioplasty, atherectomy, laser, and stent placement, with a particular emphasis on standard dimensions and other physical requirements that apply to all intraarterial devices. A list of stent types is presented in Table II .
Patients are selected for PTCA on the basis of a variety of invasive and noninvasive tests, including ECG, echocardiogram, nuclear stress test, and/or cardiac catheterization. The final decision and planning of the PTCA procedure is always based on information from the coronary angiogram, which provides the best definition of coronary anatomy, location, and severity of lesions, and the presence of collateral vessels to regions of myocardium supplied by diseased vessels being considered for PTCA ͑''target lesions''͒. In many cases this diagnostic coronary angiogram is performed immediately prior to the angioplasty procedure, significantly reducing the cost and risk compared to two separate procedures.
Because angioplasty and/or stenting is frequently performed as an acute therapy, it is common for patients to be unstable, requiring close monitoring and possible interventions such as intravenous medications, defibrillation, or placement of an intraaortic balloon pump. Patients must be closely attended by the coronary angiography team at all times during the procedure.
Arterial access: patients scheduled for angiography and/or angioplasty are usually placed on medications that include aspirin, a calcium channel blocker, and antianginal medication. In the catheterization laboratory, the patient is placed on the table, covered with sterile drapes, and the potential entry sites are prepared. An intravenous line is established for the administration of fluids and drugs, and the patient is usually placed on conscious sedation. The target artery is accessed transluminally via a puncture of an access artery, typically the common femoral artery or the brachial artery. After administering a local anesthetic the access artery is entered percutaneously with an 18 or 19 gauge hypodermic needle or a micropuncture set, a guide wire is passed through the needle into the artery, and the needle is removed, leaving the wire in place. An introducer sheath is passed over the wire and pushed through the puncture site into the artery, forming a tight seal with the puncture opening. A guide catheter is then inserted through the introducer and into the artery, forming a tight seal with the introducer. Hemostasis is completed by a rotating hemostatic valve on the Y adaptor at the proximal end of the guide catheter.
Introducer sheath and maximum size of interventional devices: the use of an introducer sheath reduces arterial trauma, particularly during interventional procedures that involve multiple exchanges of catheters and guide wires. Damage to the artery and subsequent complications are directly related to introducer sheath size, which is expressed as the diameter of the largest catheter that can be passed through it, typically 7 or 8 French (1 Frenchϭ1/ϭ0.318 mm diam). This size places an upper limit on the diameter of all angioplasty catheters of less than 2 mm, since these devices must pass through the guide catheter that must itself pass through the introducer sheath. In practice, angioplasty devices must be much smaller than this limit in order to pass through target lesions with minimum lumen diameters typically less than 1 mm. Devices that are deployed following balloon dilatation, such as stent delivery systems or intravascular brachytherapy sources, can be slightly larger than 1 mm, but systems approaching the limit set by the introducer sheath/guide catheter size will fail to negotiate many coronary arteries, even after angioplasty.
Guide catheter: guide catheters and diagnostic angiography catheters have preformed bends at the distal end to facilitate selective entry into the left or right coronary arteries. A relatively stiff guide wire keeps the catheter straight while it is advanced up the descending aorta ͑femoral approach͒, around the aortic arch and down the ascending aorta. The wire is then withdrawn, allowing the catheter to take the proper shape for entering the ostium of the target coronary artery. Contrast material is injected to visualize the artery for diagnosis or to confirm a previous angiogram, to verify the adequate placement of the guiding catheter, and to assess the size and topography of the target lesion and arterial branches.
Guide wire: when angioplasty is to be performed, the angioplasty device ͑e.g., balloon, laser, rotoblator, or stent delivery catheter͒ and its flexible intracoronary guide wire are inserted into the guiding catheter via the ''thru-port'' of the Y adaptor and advanced to the ostium. At this point the steerable guide wire alone is advanced under fluoroscopic guidance up to, across, and as far as possible past the target lesion to provide a stable guide for repeatedly advancing the angioplasty catheter across the lesion. The guide wire is necessary because balloon and other intracoronary catheters generally lack the torquability and steerability necessary to navigate through a tortuous and/or branching arterial tree. Even if intracoronary catheters had these properties, interventional procedures frequently require that catheters be placed across the lesion and withdrawn multiple times, so that a guide wire over which these catheters can be quickly and safely advanced saves time.
A wide variety of guide wires for various situations and from various manufacturers is available. The distal 20-30 cm are typically radiopaque, and the distal tip may be formable by the operator to help negotiate a particular artery, or have a permanently bent segment ͑''J'' tip͒ to facilitate steering. Standard short guide wires are at least 175 cm long. Long guide wires, or exchange wires ͑see below͒, are 300 cm long. Guide wire diameters are specified in inches, typically from 0.010 to 0.018 in. in increments of 0.002 in. Larger thickness wires are required for peripheral vessels. Wire diameter and construction determine torquability and compatibility with various balloon catheter systems. Larger wire diameter provides better torquability, but the larger wire diameter generally means the angioplasty balloon cannot be as low profile, all else being equal. Thus, low profile balloon catheters, desirable because of their superior ability to cross tight lesions, generally must be used with smaller gauge guide wires that are more difficult to maneuver into place.
Angioplasty catheters and exchange systems: it is often necessary to change balloon catheters, or, for example, to switch to an imaging intravascular ultrasound catheter or intravascular brachytherapy source catheter, while leaving the guide wire across the lesion. When this is done the guide wire must be held in place by the operator while simultaneously pulling back on the catheter. If the catheter is a central lumen, over-the-wire type, the wire must be long enough that the entire catheter can be removed from the guide catheter while the operator continues to hold the proximal end of the wire, or else friction with the catheter will pull the wire from its place across the lesion. Thus, guide wires designed to allow over-the-wire catheters to be ex-changed, so-called ''exchange wires,'' are 300 cm long, more than twice as long as the standard balloon catheter length of 135 cm. Many standard ͑nonexchange͒ guide wires, although only 175 cm long, allow an extension wire to be attached to the proximal end via a threaded or spring mechanism so that catheter exchanges may be performed. Other systems for exchanging intracoronary catheters have been developed, the most widespread of which is the ''monorail'' system that uses catheters in which only a short segment at the distal end slides along the wire, so that the wire and the catheter exit the guide catheter separately except for the last few centimeters at the distal end.
Catheter-based brachytherapy systems must meet the same general constraints as other angioplasty devices, i.e., they must be ͑1͒ small enough to pass through a standard 7 or 8 French guiding catheter; ͑2͒ flexible and pushable enough to track through tortuous anatomy with radii of curvature of 5 mm or less and diameter of 2-3 mm, without damaging the arterial wall; ͑3͒ small enough to be safely advanced through the target lesion; ͑4͒ compatible with standard guide wires and catheters, preferably with a monorail design for ease of exchange with the balloon or stent delivery catheter; ͑5͒ visible under fluoroscopy for precise localization of the dose relative to the treatment area; and ͑6͒ reliably constructed so that there is negligible risk of a device failure resulting in injury to the patient.
V. DOSIMETRY STUDIES OF INTRAVASCULAR BRACHYTHERAPY
To address some of the dosimetry related issues in intravascular brachytherapy, a brief summary of selected papers is presented in this section. Because of the sparse number of studies available in the literature, the task group was unable to present critical evaluation, reference dosimetry data, or recommendation of a quantitative nature. However, the de- scription of selected papers presented below is designed to alert the medical physics community regarding some of the pertinent dosimetry issues.
A. Dosimetry studies of gamma emitting seeds and wires
Dose distributions for point or line source gamma and x-ray emitters used in interstitial brachytherapy of cancer have been well studied both theoretically and experimentally, mostly at distances of 1 cm or more. At distances smaller than 5 mm, which are of interest in intravascular brachytherapy, measurements are difficult due to the extremely large dose gradients and other technical considerations. At small distances from the source, dose perturbations caused by scatter and self-absorption of low-energy secondary radiations also make theoretical calculations difficult.
Amols et al. 53 Ir seed between multiple slices of GafChromic™ film in a water equivalent plastic phantom for several hours. Using these dosimetry data isodose distribution in the axial plane around a linear array of five 192 Ir seeds with 2 mm spacing between seeds was calculated ͑Fig. 7͒. This dose distribution is typical of that used for the irradiation of coronary arteries in various preclinical studies. It is also typical of the doses that would be obtained with an HDR unit programmed to treat a 2-3 cm length of artery. The dose distribution at the internal surface of the arterial wall ͑approxi-mate radial distanceϭ1.5 mm) is seen to be relatively uniform ͑Ϯ10%͒ with a rapid dose falloff radially and axially beyond the extent of the implant volume ͑noted schematically in Fig. 7 by the dashed seed locations͒. The highest dose at a radial distance of 1.5 mm was normalized to 100%, and only half of the implant zone is plotted ͑the graph would be symmetric about the axial center of the implant͒. The total length of the implant volume is approximately 22 mm.
Recently Li et al. 54 used the Monte Carlo photon transport ͑MCPT, a code developed by Williamson at the University of Washington͒ simulation in the dosimetric characterization of various brachytherapy sources for intravascular brachytherapy. This study used MCPT calculations to evaluate the dose distribution of stainless steel encapsulated 192 Ir seeds at the range of 1 to 20 mm from center of the source. The results were reported using the AAPM TG-43 formalism. In particular, the radial dose function and the anisotropy function are tabulated and compared with data given in the AAPM TG-43 report. Agreement to within 3% was found between the MCPT calculation results and the AAPM TG-43 reference data for most of the data points. It was found that MCPT-derived values of radial dose function agree to within 1% with the polynomial fitted radial dose function of the 192 Ir seeds given in the AAPM TG-43 report at distances of 1 mm to 1 cm and 2% at distances between 1 and 4.5 cm. The largest discrepancies were observed in anisotropy functions along the source longitudinal axis.
B. Dosimetry studies of beta emitting seeds and wires
In 1995, Popowski et al. 55 developed a beta emitter for intravascular brachytherapy and performed extensive dosimetry measurements using thermoluminescent dosimeters ͑TLDs͒. Nonradioactive flexible 89 Y wires ͑diameter of 0.15 and 0.26 mm͒ were activated within the thermal neutron flux of an experimental reactor. Standard angioplasty balloons ͑2 cm long, 2.5 mm in diameter when inflated͒ were inserted for dosimetry into a specially manufactured tissue equivalent phantom. Four wells, drilled perpendicular to the axis of the balloon, allowed for the insertion of thin, flexible TLDs ͑disks of 2 mm diam͒ and spacers. The angioplasty balloon was inflated with air or with contrast media. Radioactive 90 Y wires were left in the central lumen of the balloon for two minutes. Doses at the surface of the balloon and at 1, 2, and 3 mm were determined from TLD readings. Doses obtained at the surface of the balloon for a two-minute exposure for the 0.26 mm wire ͑balloon inflated with air͒ and the 0.15 mm wire ͑air or contrast͒ were 56.5, 17.8, and 5.4 Gy, respectively. As expected for a beta emitter, the falloff in dose as a function of depth was rapid. External irradiation from the beta source was negligible. Popowski's experiments indicate that the dose rates attainable at the surface of the angioplasty balloon using this technique allow the doses necessary for the inhibition of intimal cell proliferation to be reached within a relatively short period of time. They conclude that the thin 90 Y wires are very easy to handle and their mechanical and radioactive properties are well suited to the requirements of the catheterization procedure.
Soares 56 presented the dose evaluation of a 90 Sr source developed for intravascular brachytherapy at Emory University. The dosimetry and characterization of this catheterbased beta-particle emitting brachytherapy source was accomplished in three distinct steps. The first step involved a characterization of seed sources to determine the axial and transaxial uniformity of each seed, as determined by measurements near contact and at 3 mm in a tissue-equivalent material such as A150 plastic. Since there were no axial orientation markings on these very small sources, uniformity of the dose rate perpendicular to the seed axis was crucial to obtaining reproducible results. Once a seed demonstrated suitable axial and transaxial uniformity, it was used in the second step, which involved the measurement of the absorbed-dose rate at a depth of 2 mm in a water equivalent medium. Next, this seed was used in the third step, which involved radiochromic film measurements at several depths in a water-equivalent phantom; the information resulting from these irradiations were then used to construct tables of data that were used to determine the dose rate at any arbitrary point in the tissue-equivalent phantom. Finally, guidance was given for determining the dose rate in media other than the tissue-equivalent material. Each of these topics are discussed in more detail in a later section of this report.
Recently, Xu et al. 57 presented dose measurements for a 32 P source developed for intravascular brachytherapy. They used TLDs for distances up to 1-5 mm and scintillation detectors. A calibration jig was developed for determining the total source activity and its nonuniform activity distribution along a 32 P source designed for endovascular irradiation. The 32 P source was 27 mm in length and 0.3 mm in diameter and was embedded in the end of a NiTi wire. The distribution of the source activity was obtained and a total activity of 12.25 mCi was determined, which was in agreement with the value measured using a well-type chamber. The radial dose rate distributions were measured using GafChromic film and calculated assuming a both nonuniform and uniform source. The results showed that the best agreement was achieved between the measured and calculated data if the nonuniform source activity was taken into account. These results have been further verified by Monte Carlo dosimetry.
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C. Dose inhomogeneity due to noncentering of source
Amols et al. 53 calculated dose asymmetry resulting from inaccurate source centering of a catheter-based system. In Fig. 8 the magnitude of the dose asymmetry resulting from centering errors of 30 mm long 90 Sr/Y and 192 Ir wires is shown. Plotted are the ratios of the maximum dose to the vessel wall divided by the minimum dose in a cylindrical vessel 5 mm in diameter as a function of centering offset. As seen, centering errors as small as 0.5 mm in a 5 mm diam vessel result in dose asymmetries of 1.6 for 192 Ir, and 2.1 for 90 Sr/Y. For catheter-based delivery systems, dose uniformity to the arterial wall depends critically on centering the source within the artery and the cylindrical symmetry of the artery itself. Amols et al. concluded that centering is more critical for beta emitters than gammas.
Dose uniformity can be improved if the design of the balloon catheter incorporates some method of centering the source. Popowski et al. 59, 60 presented a dosimetric evaluation of such a new device dedicated to intravascular irradiation, associating a beta source and a centering device prior to initiation of a clinical pilot study. A 29 mm long 90 Y coil, coated with titanium and fixed to the end of a thrust wire, was introduced into the inner lumen of centering balloons of different diameters ͑2.5, 3, 3.5, and 4 mm͒. Dose homogeneity was evaluated by studying both axial and circumferential dose variations, based on readings from TLDs placed on the Y coil activity was measured by liquid scintillation in order to relate activity to surface dose. The activity-surface dose correlation showed that for a linear coil activity of 1 mCi/mm the mean dose rate at the surface of a 2.5 mm balloon filled with contrast medium was 8.29 Gy/min. The doses at the surface of larger balloons ͑3, 3.5, and 4 mm͒ filled with contrast were 78%, 59%, and 47%, respectively, of the dose measured at the surface of the 2.5 mm balloon ͑Fig. 9͒. The coefficient of variation ͑CV͒ in the surface dose for 2.5, 3, 3.5, and 4 mm centering devices filled with contrast medium were 9%, 8%, 9%, and 12%, respectively. There was no statistically significant difference between readouts from central and peripheral balloon segments or among rows of dosimeters facing each other. For a 2.5 mm balloon compared with air, the dose attenuation by water and contrast medium was similar ͑0.70 and 0.69, respectively͒, but a significant difference was seen between the readouts of water-and contrast-filled balloons when the diameter was larger than 3 mm (pϽ0.001). No contamination was found in the balloon shaft after source retrieval. The dosimetric tests showed very good surface dose homogeneity, demonstrating satisfactory centering of the source within the centering balloons. From this study Popowski et al. concluded that the achievable dose rates will permit intravascular irradiation with a beta emitter within a short time interval.
D. Comparison of depth dose from gamma and beta rays
Calculations of dose from internally deposited beta-minus emitters is also a well-studied problem, with rigorous reports presented by Loevinger. 61 Recently, a version of this method was used by Amols et al. 51 Ir; and beta emitters 90 Sr, 32 P, and 90 Y using the ITS Monte Carlo code for the simulation of electron-photon transport. They used unencapsulated point sources of these radionuclides in these calculations, which included the entire spectra of beta and gamma emissions from each radionuclide and charged particle transport of secondary radiations ͑Fig. 11͒. They concluded that for depths up to 10 mm, even low-energy gamma emitters of 
E. Dosimetry studies of permanent radioactive stents
Fischell et al. 62 have used stents into which 32 P was permanently implanted just below the stent outer surface. Typical dimensions of the stent are 20 mm in length with diameters of 3, 4, and 5 mm. Most of the work in coronary arteries involves the 3 mm diam stent. Activities as low as 5 kBq ͑0. 13 Ci͒ have been considered. In 1995, Prestwich et al. 63 presented the results of a calculation of the dose distribution surrounding uniform cylinders of 32 P in order to obtain information relevant to the utilization of radioactive stents. The dose distribution surrounding a cylindrical source of 32 P was estimated by the dose-point-kernel method employing numerical integration. Cylinders 20 mm in length with diameters of 3, 4, and 5 mm were considered. The radial distribution is cusp shaped for planes within the length of the cylinder, becoming monotonic for planes beyond the ends of the cylinder. The dose variation from the cylinder wall was roughly exponential and the dose at a specific distance from the wall decreases with cylinder diameter.
In a later study, Prestwich et al. 64 represented the dose along the radial direction located at the midplane of a radioactive stent, simulated by a uniform cylinder of 32 P by an analytical function consisting of the sum of two modified
Ϫ1
, with no artificial normalization. ͑Adapted from Int. J. Radiat. Oncol., Biol., Phys., H. I. Amols, M. Zaider, J. Weinberger, R. Ennis, P. B. Schiff, and L. E. Reinstein, ''Dosimetric considerations for catheter-based beta and gamma emitters in the therapy of neointimal hyperplasia in human coronary arteries,'' 1996, Vol. 36, with permission from Elsevier Science.͒ exponentials. This procedure reproduces values obtained from numerical integration, for which no closed form exists, to within 5% for distances up to 6 mm from the wall and for stent diameters from 2-6 mm.
Coffey and Duggan 65 calculated the dose to tissue from a 1 Ci 32 P stent using the dose-point-kernel method, assuming the tissue outside the stent is homogeneous and uniform with properties close to that of water. The cylindrical geometry for a Palmaz-Schatz coronary stent was introduced into the model calculation since this device is the most widely used coronary stent. Dose maps were calculated for distances ranging from 0.1 to 3 mm radially out from the stent surface. The results were compared to actual measurements made using radiochromic film dosimetry from a 32 P impregnated Palmaz-Schatz stent produced by an ion implantation process. In this study, verification of the Prestwich model for 32 P stents ͑modified Strecker and Palmaz-Schatz͒ was provided by measuring a dose for the radial distance from 0.5 to 5 mm from the stent surface using radiochromic film dosimetry ͑Fig. 12͒.
Duggan et al. 66 described a model similar to the point dose kernel models of Berger, Brookeman, and Prestwich for the estimation of the dose distribution surrounding a pure beta-emitting 32 P coronary stent. In addition, radiochromic dosimetry methods were utilized to experimentally determine the absolute dose and relative dose distributions parallel to the short axis of a 
Janicki et al. 67 calculated the near-field dose distribution of a realistic 32 P impregnated vascular stent employing the dose-point-kernel method in a homogeneous medium. The cylindrical wire mesh geometry for the Palmaz-Schatz stent was numerically introduced in the model calculation, and the dose distribution of the 32 P beta emitting isotope was computed at distances ranging from 0.1 to 3 mm from the outside of the stent surface. Measurements made using radiochromic film dosimetry of the dose from Palmaz-Schatz stents impregnated with 32 P produced by shallow ion implantation were used to validate the model at radial distances from 0.11 to 4 mm from the stent surface and axial distances of up to 4 mm from the center of the stent ͑Fig. 14͒. The close agreement between the model and the film dosimetry results confirmed the validity of this geometry-specific model. As reported recently by Janicki et al., 68 this calculational dosepoint-kernel methodology can be adapted to any stent design to yield dose distribution results. Finally, Whiting et al. 69 reported computed dose distributions surrounding a PalmazSchatz stent using the Monte Carlo N-particle ͑MCNP͒ transport code, which agreed well with the results from Janicki's model.
In 1995, Ly et al. ͑aka Li͒ 70,71 reported a feasibility study and preliminary dosimetry for a brachytherapy source based on proton-beam activation of a removable intracoronary stent made of shape-memory nickel-titanium alloy ͑Nitinol™͒. The stent was activated by 8.5 MeV proton bombardment to produce Vanadium-48:
48 Ti(p,n) 48 V. Due to the high attenuation of the protons by Nitinol, the stent was rotated axially during proton bombardment to achieve uniform activation. A 16.0 day half-life and gamma emissions of 0.511, 0.945, 0.983, 1.312, and 2.241 MeV were measured by spectral analysis to confirm the production of 48 V. All other activation products were decayed to the background by three days. Despite the presence of penetrating gamma emissions, over 96% of the dose within 1.0 mm of a 48 V stent was from positron absorption, and the dose at 10 cm from the stent was less than 0.02% of the treatment dose. GAF Chromic™ film ͑23 m thick active polymer emulsion͒ was calibrated with a 60 Co radiation treatment beam and was used to measure dose distributions for five planes parallel to the stent long axis, spaced 126 m apart. The complete three-dimensional dose distribution surrounding the stent was estimated by computing the dose distribution for a single ''strut'' segment by Monte Carlo calculation ͑MCNP version 4a͒, then using this as a ''strut dose kernel'' to perform a summation over all 48 struts making up the stent. The absolute dose based on this calculation and measured total 48 V activity agreed with the direct radiochromic film measurements to better than 10%. Full three-dimensional dose distributions can be computed for stents expanded to any diameter, and even for irregularly deployed stems, allowing detailed dose descriptions throughout the treatment volume ͑an example is shown in Fig. 15͒ . 
F. Dosimetry studies of radioactive liquid filled balloon catheter
One possible irradiation technique, presented by Amols et al. 72 is to inflate the balloon dilatation catheter with a radioactive solution. It has advantages over other proposed irradiation procedures, in that accurate source positioning and a uniform dose to the vessel wall are assured as long as the artery is not already stented. Experimental measurements and analytical calculations of the dose distribution around a 3 mm diam by 20 mm long balloon filled with a 90 Y-chloride solution were also presented. The dose rate at the surface of the balloon was approximately 0.14 cGy/s per mCi/ml (3.78ϫ10 Ϫ11 Gy/s per Bq/ml, with the dose decreasing to 53% at 0.5 mm, and Ͻ5% at a 3.5 mm radial distance. Whiting et al. 69 have shown that unlike solid intracatheter sources and stents, the dose rate at a given depth in tissue from a liquid isotope balloon source increases with an increased vessel size. Amols et al. 72 concluded that 90 Y and other possible isotopes are currently available at specific concentrations у50 mCi/ml (1.85ϫ10 9 Bq/ml), which enables the delivery of 20 Gy in less than five minutes. In Fig. 16 , the calculated and measured dose rate versus the radial distance from the center of a 3 mm diam by 20 mm long balloon (total volumeϭ0.14 ml) filled with a 90 Y solution are shown. The dose is plotted in units of cGy s Ϫ1 mCi Ϫ1 ml
Ϫ1
. The measured data were obtained using GafChromic film, as described above. Agreement between measurements and calculations is Ϯ3%. While this technique clearly yields desirable dose distributions, the chemical and radiological toxicity of the radioactive liquid must be considered, as there is a risk of balloon rupture with present catheter design ͑approximately 0.1%͒. Since most commonly available beta emitters ͑and all of those listed in Table I Re generator is not a bone seeker and is eliminated via the urine with a biological half-life of about 10 h͒ are bone seeking compounds, the whole body and bone marrow doses that would ensue after a balloon rupture are unacceptably high ͑100-1000 cGy͒. New data on 90 Y and 188 Re chelates, which have short biological half-lives, indicate that those risks may be reduced to a tolerable level.
VI. RECOMMENDATIONS FOR INTRAVASCULAR BRACHYTHERAPY PHYSICS
A. Dose specification and renormalization for catheter-based intravascular brachytherapy systems
The irradiation techniques and specification of radiation doses in various studies using catheter-based intravascular brachytherapy differ from each other significantly, making a direct comparison of the techniques difficult. This AAPM task group reviewed the dosimetry of these catheter-based intravascular brachytherapy techniques. An initial review indicated that different investigators have employed different methods of dose specification. Some were using the dose to the adventitia, some to the wall of the lumen, and some at varying radial distances from the source center. This created a great deal of confusion regarding the efficacy reported in different studies at different dose levels. Therefore, the task group decided to undertake a major scientific effort to renormalize the dosimetry to a common framework. This original analysis was divided into three groups: ͑1͒ catheter-based systems using gamma emitters for peripheral vessels; 40,43 ͑2͒ catheter-based systems using gamma emitters for coronary vessels; 45, 32, 33, 30, 44 and ͑3͒ catheter-based systems using beta emitters for coronary vessels. 59, 60, 37 In order to use a common frame for comparing the dosimetry, it was assumed that in the peripheral vessel studies the inner diameter of the vessel is 6 mm and in the coronary arteries it is 3 mm. Assuming these common dimensions, the doses to the luminal wall and at depths of 1, 2, and 3 mm from the walls were calculated.
Catheter-based intravascular brachytherapy for peripheral vessels using gamma emitter
Liermann et al. 40 reported the use of a remote afterloading unit ͑Nucletron MicroSelectron HDR͒ delivering an 192 Ir source of 10 Ci activity to the restenosis site in human femoropopliteal arteries. The delivery technique used a 5 French close-ended catheter inserted into a non-self-centering 9 French catheter ͑diameter 3 mm͒. The prescription is specified as delivering 12 Gy to a distance of 3 mm from the center of the source. The vessel segment has a diameter of 6 mm by use of an expanded 6 mm stent. It is therefore assumed that the vessel lumen surface is given 12 Gy. Depth dose calculations were performed to obtain doses of 8.77, 5.51, 3.96, and 3.03 Gy at 4, 6, 8, and 10 mm from center of the source, respectively. Actual minimum and maximum doses delivered to the vessel wall were reported to be 8 and 28 Gy, due to the deviation of the catheter from the center of the vessel. 73 Waksman et al. 43 used another remote afterloading ͑Om-nitron͒ unit for treatment of narrowed arteriovenous grafts, giving a higher dose of 14 Gy at a depth of 0.5 mm from the arterial wall. They have since then decommissioned the remote afterloading unit and switched to the same unit that Liermann et al. 40 used. A non-self-centering catheter is used.
Since the same remote afterloading unit and treatment planning system is used, it is relatively easy to compare the dose specifications used in these studies. The ͑Nucletron MicroSelectron NPS/PLATO͒ treatment planning system used for this remote afterloading unit has optimization algorithms that, in this treatment geometry, in effect increase the source dwell times for dwell positions at the ends of the treated length, so as to maintain dose homogeneity along the treated vessel. The dose calculation algorithm models the source ͑3.5 mm active length, 5 mm physical length͒ as a point source, but is able to perform calculations based on dose distribution anisotropy data at one given distance from the source center. Tissue attenuation and scattering are corrected for using the formula given by Van Kleffens and Star. 74 For the renormalization of dose specifications presented here, optimized dwell times are calculated using the same treatment planning system, with optimization on dose points placed at prescription distances from the source center for a treated length of 4.5 cm with nine dwell positions, with a dwell position step size of 5 mm. These dwell times are used to calculate the renormalized dose distribution, corrected for dose distribution anisotropy using the data from Williamson 75 The diameter of the treated vessel is assumed to be 6 mm.
Results of the renormalization process are given in Table  III . Average as well as the minimum and maximum doses along the inner 4 cm of the treated length, calculated with a 1 mm grid size, are also given. It can be seen that the failure to account for the dose distribution anisotropy, especially the oblique filtration by source encapsulation, results in a 6%-10% deviation in the actual delivered dose from the nominal prescription dose. In addition, the dose distribution inhomogeneity is underestimated by the computer treatment planning system calculations, though to a smaller extent.
Catheter-based intravascular brachytherapy for coronary vessels using gamma emitters
192
Ir seeds of the same design as those used in conventional low dose rate brachytherapy, but with higher activity per seed, are also used for the treatment of coronary vessel restenosis. Teirstein et al. 45 uses ribbons of stainless steel encapsulated 192 Ir seeds, at activities up to 150 mCi per ribbon, to deliver a nominal prescription dose of 8 Gy to the plaque and media region of human coronary vessels. The interseed center spacing between 192 Ir seeds is 4 mm, and two lengths of ribbons, one using five seeds to obtain 1.9 cm active length and the other using nine seeds to obtain 3.5 cm active length, are used. The ribbon is manually inserted into a non-self-centering 4 French catheter. Ultrasound scans are obtained during the implant procedure to ensure that the minimum and maximum doses to the media remain within the range of 7 to 30 Gy. Dosimetric data for the ribbons at the treated distance ͑average 3.2 mm from the center of the sources͒ is based on those by Kline et al. 76 Weinberger's group 30 Ir seeds in an animal coronary vessel study. The 3 mm long seeds were contained in the plastic ribbon, with no spacing between the seeds ͑3 mm interseed center spacing͒. The study prescribes a dose of 3.5, Condado et al. 44 reported the clinical experience of using an 192 Ir wire of 1.5 Ci activity delivered manually into coronary vessels. The dose is specified as delivering 20 or 25 Gy at a distance of 1.5 mm from the center of the source. A non-self-centering 4 French catheter is used in the study.
It should be noted that while both the Teirstein group and the Condado group used non-self-centering 4 French catheters only for the delivery of treatment, the former group adjusted treatment time using ultrasound measured media thickness, to ensure that no part of the vessel wall received more than 30 Gy dose, while the latter group exercised no adjustment of the treatment time based on individual patient measurement. The resulting hot spot in the latter case therefore can be more than 50 Gy, based on a prescription of 25 Gy to 1.5 mm distance from the center of 192 Ir wire, using the Sievert integral approximation.
Renormalization of prescribed doses as well as the dose distribution at other points within the treated volume is performed in the same manner as the case for peripheral vessel intravascular brachytherapy. For
Ir ribbon-based techniques, the source activities and treatment times are first determined from the nominal prescription doses, using the Kline et al. 76 data for the Teirstein et al. 45 technique and the Condado et al. 44 technique, and the point source approximation for the Waksman et al. 32, 33 technique and the Weinberger 30 technique. These activities and treatment times are then used to recalculate dose distributions, using radial dose function and anisotropy function data calculated by Monte Carlo photon transport simulations 54 for distances smaller than 1 cm, in combination with the AAPM TG-43 report 52 data for distances larger than 1 cm, while the dose rate constant data are from the same AAPM task group report. The average, minimum, and maximum doses are calculated using the 1 mm calculation grid size along the treated length, delimited by the centers of the 192 Ir seeds at ends of the ribbons. Coronary vessels are assumed to have a diameter of 3 mm. The treated lengths are as specified by the respective studies. Results of the renormalization are given in Table IV below. It can be seen that, due to the close distance at which prescribed doses are specified, there can be significant uncertainty in the dose actually delivered.
Catheter-based intravascular brachytherapy using beta emitter
Two groups have reported use of a beta-emitting source in catheter-based intravascular brachytherapy. The Popowski group 59, 60 in Berne, Switzerland, developed a balloon-fitted catheter that is capable of self-centering within a coronary vessel when the balloon is inflated. A 90 Y wire was then used in this catheter for treatment. Dosimetry data were obtained using a TLD measurement technique. Waksman et al. 37 experimented with a 2.5 cm long source train of five 77 Dose distribution data from these reports are used directly to obtain the values given in Table V.
Recommendations on dose prescription for a catheter-based system
Results of the above analysis indicate a wide variation in dose specification for catheter-based intravascular brachytherapy, in the extreme case by as much as 56%. When these results were first presented to the cardiology community it became apparent to them that a careful analysis of dosimetry by a qualified medical physicist has great merit in making a meaningful evaluation of the results of preclinical and clinical studies using ionizing radiation. These data ͑Tables III-V͒ have, in fact, resolved a puzzling lack of efficacy in some of the studies by showing that the reported doses were, in fact, too low compared to those in other studies showing efficacy because of the choice of a different point for dose specification.
Based upon the above analysis of dose specification and its renormalization in preclinical and clinical studies on catheter-based studies, the task group recognizes that a uniform practice of dose reporting is needed. To this end, the task group recommends that prescription for a catheter-based system should be in terms of a dose delivered at a reference 40, 1996 , with permission from Elsevier Science.͒ distance in water. For intracoronary application, a reference distance of 2 mm from the source center is recommended. For a larger, peripheral vessel the reference distance should be 2 mm larger than the average lumen radius of the vessels under study.
For the coronary arteries, the choice of 2 mm as a reference distance provides a dose specification relative to the source location, which can be easily reproduced and verified by a data review committee in a multi-institutional study. However, it suffers from the fact that it does not express dose delivered to an anatomical structure, e.g., the lumen wall, adventitia, etc. In fact, for any given patient the lesion is likely to be eccentric and vary in thickness and eccentricity along its length; therefore doses to any given anatomic structure such as the lumen wall are going to vary widely. The recommendation regarding dose specification for peripheral vessels is dose at a depth of 2 mm from the average lumen radius because peripheral vessels can be much larger than coronary vessels. In a larger vessel the centering of the catheter-based source becomes more important because of the larger potential for eccentricity and consequently hot and cold spots.
Ideally a three-dimensional dose distribution over the entire irradiated volume should be generated for each specific patient. If detailed three-dimensional quantitative measurements such as those from an IVUS study are available, the average, minimum, and maximum doses delivered should be estimated for each clinical case. These dosimetry parameters should be determined in at least three planes perpendicular to the catheter and along its length over the lesion.
Because of the potential of a significant market, a large number of commercial vendors are developing various delivery systems for intravascular brachytherapy. In order to evaluate different systems it is important to compare them using a common specification. Even though it is too early to develop a rigid standard for intravascular brachytherapy sys- tems, the task group strongly recommends that the following minimum specifications should be used in evaluating all catheter-based systems.
͑1͒
The output of all commercial systems for coronary applications should be specified in terms of dose rate in water at a radial distance of 2 mm from the center of the source. ͑2͒ The penetrating ability of all commercial systems should be specified in terms of the radial dose function normalized at a radial distance of 2 mm. The radial dose function should cover at least a range of radial distances from 0.5 to 10 mm ͑or R 90 , 90% of the electron range for beta emitters͒ at 0.5 mm intervals. ͑3͒ Uniformity of the dose delivered at points along the source-axis should be better than Ϯ10% ͑range of values from minimum to maximum in the centered twothirds of the treatment length of at least 3 cm͒ at a radial distance of 2 mm from the source axis. ͑4͒ Uniformity of a dose at the points in a circle of 2 mm radius centered on the course axis should also be within Ϯ10% in the centered two-thirds of a minimum treatment length of 3 cm.
These task group recommendations are achievable by most of the commercial systems. Therefore, it is considered to be a reasonably attainable standard.
B. Dosimetric characterization of catheter-based intravascular brachytherapy systems
Dosimetry of catheter-based gamma emitters
The AAPM recommends the use of the TG-43 dose calculation formalism for catheter-based intravascular brachytherapy systems using photon-emitting sources. The TG-43 formalism recommends that the dose at a point (r,), as shown in Fig. 17 , be calculated using
where S K ϭair kerma strength, ⌳ϭdose rate constant, r ϭradial distance from the source, ϭangle between the line segment from point of interest to center of source, as measured from a line containing the source's long axis, F(r,) ϭanisotropy factor describing the dose variation versus angle. This function is normalized to unity at ϭ90°, G(r,)ϭgeometry factor resulting from spatial distribution of the radioactivity within the source, g(r)ϭradial dose function, and (r 0 , 0 )ϭthe polar coordinates of the reference point. The reference point recommended by TG-43 is the point on the transverse axis at a distance of 1 cm, i.e., r 0 ϭ1 cm and 0 ϭ/2. Under the point source approximation, the geometry factor and radial dose function are 48 V, total activity 5.0 Ci. Left and right plots are for the most uniform ͑''12-strut'' section͒ and least uniform ͑''6-strut'' or mid-slot section͒ cross sections, respectively, for both stents. The activities were chosen to give approximately the same dose of 12 Gy to a depth of 0.5 mm ͑outer dashed circle͒ for both stents. Note that the dose for the 32 P stent is significantly more homogeneous than that for 48 V, which has a maximum beta energy of only about half that of Using the TG-43 notation, the dose at a distance r from a source under the point source approximation can be expressed as
where avg is the average anisotropy factor. For a line source, the geometry factor is
where ␤ is the angle subtended by the active length L at the point of interest. The strength of the gamma-emitter source should be determined in terms of its air kerma strength, as described in the AAPM TG-43 report. The air kerma strength of the intravascular brachytherapy source should be traceable to a NIST standard or to an ADCL standard. For gamma-emitting sources these procedures for the specification and determination of source strength are identical to those described in the TG-43 report.
Because distances of interest in intravascular brachytherapy are much smaller than the conventional brachytherapy reference distance of 1 cm, it is recommended that the reference distance for intravascular brachytherapy dosimetry be r 0 ϭ2 mm. In order to avoid confusion with TG-43 terminology, the following modified notation is recommended to generalize Eq. ͑1͒:
where ⌳ r 0 is the dose rate constant at a reference distance of r 0 , and g r 0 is the radial dose function normalized to a radial distance of r 0 and given by Eq. ͑2͒ for a point source.
The radial dose function for intravascular brachytherapy should be expressed with a reference point at 2 mm. Similarly, the dose rate constant ⌳ r 0 should also use the reference distance of 2 mm i.e., it should be the dose rate at a reference distance of 2 mm in water from a source of unit air kerma strength. All relative dosimetric parameters such as g r 0 (r); G(r,); and F(r,) should be measured for each specific type and model of a delivery system. However, all users do not have to measure these parameters as long as they have verified the validity of the parameters used.
Dosimetry of catheter-based beta emitters
Because national standards for the air kerma strength of beta-emitting sources do not exist, the AAPM recommends that the dose at a point (r,) be determined using D͑r, ͒ϭD͑ r 0 , 0 ͓͒G͑ r, ͒/G͑ r 0 , 0 ͔͒g͑ r ͒F͑ r, ͒, ͑6͒
where D(r 0 , 0 ) is the dose rate in water at the reference point (r 0 , 0 ). The reference point for intravascular brachytherapy calibration for beta sources should be r 0 ϭ2 mm and 0 ϭ/2. All other quantities have the same meaning as in the case of gamma emitters. For the calibration of betaemitting sources, i.e., the determination of D(r, 0 , 0 ), the method used by Soares et al. 56 or an equivalent method, should be used. Soares et al. measured dose rate averaged over a 1 mm diam area from current measurements with an Assuming a lumen diameter of 6 mm and exact source centering.
extrapolation ionization chamber with a graphite electrode. In this case, the absorbed-dose rate to A150 plastic in Gy/s at the surface of the plastic was given by
where (⌬I/⌬d) 0 ϭthe rate of change of current ͑normalized to a reference temperature and pressure͒ with extrapolation chamber air-gap thickness as the thickness approaches zero, in units of nA/mm, 33.97ϭthe average energy in Joules needed to produce one Coulomb of ions of either sign in air, 1.13ϭthe ratio of the mean mass stopping power of A150 plastic to that of air, 1.197ϭthe density of air at the reference temperature and pressure ͑22°C and 1 standard atmosphere͒ in kg/m The overall uncertainty in the calibration is estimated by Soares to be Ϯ15%.
Finally, some guidance is given for converting from the dose in A150 plastic to the dose in water or some other medium. While A150 might not be the ideal choice for a water-or tissue-equivalent material for beta particles, it does have the advantage of being a conductor, and thus avoiding the charge buildup problems characteristic of the high dose rates possible from these sources. For point sources in infinite media, the dose at a distance r m corresponding to an aerial density of r m m ͑in g/cm 2 ͒ in the medium, D m (r m m ), is related to the dose in water, at the same aerial density, r w w , but scaled by
where is the scaling factor of the medium relative to water, 
Recommendations on dose calibration of catheter-based system
The AAPM recommends that the dose rate from a catheter-based system using photon emitters be determined using the dosimetry protocol described by AAPM TG-43, with the modification that the reference distance be 2 mm instead of the conventional reference distance of 1 cm. For photon sources, the source strength should be measured in terms of air kerma strength. The penetrating ability of the radiation should be described by the radial dose function normalized at 2 mm and its angular dependence by the anisotropy function.
For beta emitters in a catheter-based system, the AAPM recommends the same protocol, except that the source strength cannot be expressed in terms of air kerma strength. Instead, the source strength in this case should be specified in terms of the dose rate in water at a reference distance of 2 mm.
In order to develop a consistent set of specifications of their equipment, manufacturers of catheter-based systems should express the output in terms of a dose rate in water at a distance of 2 mm, and use radial dose function and anisotropy functions over a distance of 10 mm to describe the dose distribution around their products.
C. Dosimetric characterization of radioactive stents
Analogous to the previous case of catheter-based brachytherapy, analysis by the task group revealed a confusing variety of different dose specifications in radioactive stent implantation. Again, the task group undertook a major effort to analyze all existing clinical studies of radioactive stents using a common framework. We chose a depth of 0.5 mm from the surface of the stent as the reference depth and a total treatment time of 28 days as a common framework for this purpose. The 28 day period has also been the most commonly used time to sacrifice in the animal studies in this area.
Dosimetry of the following four radioactive stent studies 37, [79] [80] [81] were reviewed by the task group using a common approach that was selected to be the numerical integration model of Prestwich. The results of this evaluation are shown in Table VI . The dose at 0.5 mm depth given in 28 days varies widely from 0.6 to 414 Gy in these studies, which is not surprising because different activities were chosen deliberately by the investigators. The more interesting observation is that the dose delivered per unit activity for the same radionuclide varied by almost a factor of 4. The dose normalized per Ci of 32 P varied from 4.5 to 19.6 Gy/Ci, indicating the effects of stent type, diameter, and length. In most cases, the dose to 28 days was reported because that was also the time to sacrifice. Direct comparison of dose delivery by stent versus an acute catheter-based irradiation is complicated because the dose rate effects are different. There is some evidence that the dose delivered acutely more than three days after angioplasty is not effective in reducing neointimal proliferation. But it is not known whether this applies to a continuous low dose rate delivered by stents. We have arbitrarily chosen to tabulate the dose delivered in 28 days, recognizing that biological effects may correlate better with other dose descriptors. Again, it is necessary to evaluate dosimetry consistently from study to study so that meaningful conclusions can be made from clinical and preclinical studies.
The location of the dose calculation point for intravascular brachytherapy must be specified differently for radioactive stents and catheter-based sources. The AAPM recommends that clinical prescription of radioactive stents should be based upon the dose rate at a distance of 0.5 mm from the Assuming a lumen diameter of 3 mm and exact source centering.
surface of the stent. If the vessel diameter is 3 mm, for example, the dose calculation point for a catheter-based source would typically be specified as 2 mm from the center of the source. This same point would be 0.5 mm from the surface of a radioactive stent, and should be specified as such.
Another question peculiar to a permanently implanted radioactive stent is that of treatment time. Since neointimal hyperplasia in a stented artery occurs in the first few weeks to two months after stent placement, only the dose delivered during this period is effective. Hence, an effective treatment time should be specified; 28 days is reasonable.
For the specification of the strength of radioactive stents, the AAPM recommends that the activity, nominal diameter, deployed diameter, length, type, and model be specified for each individual case. It is also recommended that doses radial to a stent can be calculated using beta point dose kernels. The axial dependence of the dose at a fixed radial distance can be calculated by the cylindrical shell method of Prestwich et al. 63 and Duggan et al. 66 for a uniform distribution of 32 P on the outside of the stent, and Janicki et al. 67 for the Palmaz-Schatz geometry ͑Figs. 13-14͒ or the advanced stent design model. 68 All of these dose models, except for the latter, have been verified by radiochromic film dosimetry.
A difficulty with determining the activity and consequently calculating the dose of a 32 P stent is the necessity that the stent remain sterile for patient use. The stents are shipped in a Plexiglas safety cylinder with sufficient wall thickness to absorb all the beta particles. Although the beta particles are absorbed within the Plexiglas walls of the shipping container, bremsstrahlung x rays are produced. Larsen and Mohrbacher 82 have reported a technique to determine 32 P activity by bremsstrahlung counting methods. The bremsstrahlung x rays detected are directly proportional to the number of betas emitted. Also, it is assumed that no other contaminating radionuclides are present in the sample.
In preliminary experiments, Coffey and Duggan 65 have demonstrated that a NaI͑Tl͒ scintillation crystal and a multichannel analyzer ͑MCA͒ can be used to count bremsstrahlung x rays from low activity 32 P stents. Early experiments indicate that individual determinations of the activity of each stent can be achieved to an accuracy of Ϯ10% while maintaining sterility.
The source activity of mixed beta-gamma emitters may be conveniently measured by counting the gamma photo peak in standard geometry, with a possible correction for the bremsstrahlung continuum if necessary. In the case of a positron emitter such as 48 V, the 511 keV annihilation photons provide another simple solution. Because the maximum beta energy for 48 V is only 696 keV, bremsstrahlung makes no significant contribution at 511 keV, and absolutely none at the strongest gamma energy of 1.15 MeV ͑100%͒ of 48 V, so activity can easily be determined with a calibrated detector with a lower-energy threshold, just including the 511 keV photo peak, or even in a calibrated ionization well chamber in a beta-absorbing plastic shield. The small gamma contribution to the dose distribution may be calculated using a point dose kernel integration, but the beta dose distribution is best calculated using a Monte Carlo technique that can properly account for absorption of the emitted betas within the metallic stent material. This is more important for the proton activated 48 V stent because its activity is distributed throughout the stent metal and has a relatively low energy compared to the higher-energy betas from 32 P distributed only on the stent outer surface.
NIST does offer a reference standard 32 P source for activity analysis. The user can use a number of relative calibration procedures including a well-type ionization chamber, 83 an NaI͑Tl͒ scintillation counter, or a liquid scintillation counter. For the particular counting method chosen, a calibration factor traceable to NIST must be available. The NIST standardization process utilizes a high efficiency liquid scintillation counting method. Solutions standardized by this technique may then be used to establish the counting efficiencies for various practical sample geometries for reentrant ionization chamber dose calibrations and NaI͑Tl͒ photon counters. These very practical transfer techniques are exceedingly useful for relative measurements, but standards are needed to first calibrate the instrument. 84 An unacceptably large error may be encountered if one compares sources of different geometries in these ''secondary instruments.''
D. Recommendation of clinical prescription and dose reporting of radioactive stents
The measurement of dose distributions in close proximity to a radioactive stent is a monumental task, which need not be repeated for each clinical case. Instead, reasonably consistent treatments can be achieved by specifying the activity implanted in a given stent model provided the geometry is carefully reported. Therefore, the AAPM recommends that for each type of radioactive stent the three-dimensional dose distributions around stents of various lengths, diameters, and activities should be carefully determined by benchmark dosimetry studies before clinical implementation. Also, it is recommended that for each radioactive stent procedure the activity of the stent, its nominal diameter, deployed diameter, length, type, and model be used for a clinical prescription, and doses delivered at a depth of 0.5 mm from the surface of the stent in the midplane and over a time period of 28 days should be reported for treatment and evaluation. Although the dose to full decay and the dose over several time periods is important for a full evaluation of biological and clinical results, the task group recommends a dose accumulated over 28 days as a common reference time. Even for different radionuclides of varying half-lives, most animal studies in this field use 28 days as the time to sacrifice for endpoint evaluation.
E. Quality assurance and safety aspects
A comprehensive quality assurance ͑QA͒ program is required for intravascular brachytherapy to assure consistency, accuracy, and safety of the personnel involved. Several reports on QA for conventional brachytherapy exist in the literature. [85] [86] [87] [88] [89] In this section we describe QA aspects as they relate to intravascular brachytherapy procedures. Specifics of a QA program depend to an extent on the technique utilized in intravascular irradiation. Four major techniques being explored at present are ͑1͒ manually loaded sealed sources; ͑2͒ remotely loaded sealed sources; ͑3͒ radioactive stent placement; and ͑4͒ radioactive liquid balloons. Essential elements of a comprehensive QA program for each of the above techniques, except for radioactive liquid balloons, are described below. For radioactive liquid balloons, there is insufficient information in the literature to recommend a quality assurance program. For the first three techniques the following items should be part of a QA program.
͑1͒ Document in detail the essential properties ͑radiation and physical͒ of the radioactive source. ͑2͒ Develop protocols to be followed for the purchase and receipt of sources in collaboration with the institution's radiation safety officer ͑RSO͒. For remotely loaded sources, develop acceptance testing and commissioning procedures. ͑3͒ Develop guidelines to safely store the radioactive sources and control their access and perform periodic inventory of the sources and enter the results in log books. ͑4͒ Check the physical integrity of the sealed sources prior to use and perform leak tests. Remotely loaded sources require an extensive routine QA procedure, which includes ͑1͒ room safety interlocks; ͑2͒ lights and alarm functions; ͑3͒ console functions ͑including audio/visual͒; ͑4͒ switches and batteries; ͑5͒ visual inspection of source guides; ͑6͒ accuracy of the source preparation using an autoradiograph; ͑7͒ source positioning accuracy ͑dummy loading and real source loading͒; ͑8͒ the timer function; ͑9͒ calibration of source activity; ͑10͒ mechanical integrity of the applicators; and ͑11͒ emergency response. Details of these procedures have already been described.
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͑5͒ Develop a methodology to verify source activity using in-house equipment such as dose calibrators, reentrant chambers, etc. ͑6͒ Develop methods to properly sterilize sources when required. Open-ended afterloading catheters employed in intravascular irradiation come in contact with patient's body fluid and hence require sterility. ͑7͒ Develop protocols to safely transport radioactive material from a room to a sterilization department and then onto a catheterization room. ͑8͒ Develop the protocol to safely dispose of the sources after the procedure or to store the unused sources on site. ͑9͒ Assure all the needed ancillary equipment ͑e.g., long forceps, stopwatch, scissors, etc.͒ are readily available on a tray at the time of the irradiation procedure. ͑10͒ Develop protocols to be followed in case of unexpected emergencies. Some urgent instances are ͑1͒ source breakage and contamination; ͑2͒ loss of a source within vasculature of the patient; ͑3͒ loss of a source in the catheterization room; ͑4͒ cardiac or respiratory arrest ͑related or unrelated to the irradiation procedure͒; and ͑5͒ emergency surgery. All emergency procedures should be coordinated with the RSO. For example, an emergency lead container must be present in the room during the entire procedure for use by physicists/RSO. ͑11͒ Develop a protocol that describes the role of each individual in this interdisciplinary procedure. A working team for intravascular irradiation protocol must include ͑1͒ an interventional cardiologist or radiologist; ͑2͒ a radiation oncologist; ͑3͒ a radiotherapy physicist; ͑4͒ a health physicist; and ͑5͒ a nurse/coordinator. Each individual should know the role he/she is expected to fulfill during this procedure. The duties of the health physicist in this procedure may be assigned to the radiotherapy physicist. ͑12͒ Develop a form for the dose prescription ͑written directive͒ to be filled by the authorized user prior to the initiation of irradiation. ͑13͒ Develop and document the dosimetric methods employed in computing the irradiation time. The calculation should be independently verified and signed prior to initiation of the procedure. ͑14͒ Verify that the correct sources chosen for irradiation and that all treatment planning parameters used correspond to that patient. ͑15͒ Monitor radiation levels around the patient/room during the procedure. ͑16͒ Perform and document radiation protection surveys at the end of the procedure as mandated by state/federal regulations. ͑17͒ For permanent implants of a radioactive stent, the patient needs to be given a complete instruction on safety and follow-up aspects. This is normally accomplished at the time of patient discharge. ͑18͒ Develop a program to routinely provide education and training on radiation protection to all the staff members involved, including physicians, nurses, and ancillary personnel.
VII. SUMMARY OF RECOMMENDATIONS
͑1͒
The source strength of a catheter-based system should be expressed in terms of the air kerma rate in air for gamma sources ͑air kerma strength͒ and the dose rate in water at a reference distance of 2 mm for beta emitters.
͑2͒ Dose distributions around a catheter-based brachytherapy source should be determined using the AAPM Task Group No. 43 protocol for photon sources and a modified version of the AAPM Task Group No. 43 protocol for beta sources.
͑3͒ The source strength of a catheter-based system should be traceable to a national standard at NIST or at an ADCL.
͑4͒ The radial dose function, geometry function, and anisotropy function should be determined for each specific source design of a commercial catheter-based system. ͑5͒ The clinical prescription for a catheter-based system should be expressed in terms of the dose delivered at a reference depth in water.
͑6͒ For a catheter-based system, the depth of dose prescription for intracoronary applications should be at a radial distance of 2 mm from the center of the source and for peripheral vessels 2 mm larger than the average lumen radius. An average lumen radius should also be reported.
͑7͒ For optimal assessment of each clinical case, average, minimum, and maximum doses delivered should be estimated in at least three planes perpendicular to the catheter and along its length.
͑8͒ The output of all commercial intravascular brachytherapy catheter-based systems should be specified in terms of the dose rate in water at a radial distance of 2 mm from the center of the catheter.
͑9͒ The penetrating ability of all commercial intravascular brachytherapy catheter-based systems should be specified in terms of the radial dose function normalized at a distance of 2 mm and at radial distances from 0.5 to 10 mm ͑or R 90 , 90% of the electron range for beta emitters͒, at 0.5 mm intervals, with a reference depth of 2 mm. ͑10͒ Uniformity of the dose delivered by catheter-based systems at points both along the source axis, at rϭ2 mm, and around the circumference of a 2 mm radius circle centered on the source axis in a plane perpendicular to it should be better than Ϯ10% ͑the range of values from minimum to maximum in the centered two-thirds of the treated length of at least 3 cm along the catheter axis͒.
͑11͒ For each catheter-based system, an atlas of threedimensional dose distributions should be generated to estimate the dose variation in the target.
͑12͒ The clinical prescription of radioactive stents should be in terms of ͑1͒ stent diameter, nominal and deployed; ͑2͒ stent length; ͑3͒ stent type, brand, model; ͑4͒ radioisotope; and ͑5͒ activity.
͑13͒ The measured activity of a radioactive stent should be traceable to a national standard at NIST.
͑14͒ Activity for each radioactive stent to be used should be determined using an appropriate transfer technique.
͑15͒ For radioactive stents, doses at 0.5 mm radial distance from the surface of the stent in the midplane and over time periods of 28 days should be reported.
͑16͒ The quality assurance program presented in this AAPM task group report should be followed under the direction of a qualified medical physicist.
VIII. FUTURE CONSIDERATIONS
One of the controversies in the current literature is regarding the optimal choice of a radionuclide for a catheter-based system. The ideal catheter-based source would have high activity in a small volume, long half-life ͑to reduce the cost͒, uniform dose over treatment distances of 2-3 mm from the source center, and a low cost. No available isotope is ideal. Beta emitters such as 32 Ir have advantages in terms of radial dose uniformity, high dose rate, and reasonably long half-lives. Each isotope could be fabricated at the required activities and size using the current technology. There is a tradeoff between the increased radial range of gamma emitters and the safety advantages of beta emitters. Because of the large amount of shielding required and the high activity for gamma emitters, it is possible that safety considerations may require that gamma emitters be used only with specially shielded remote controlled units. Beta emitters, on the other hand, may be usable via hand loaded techniques, thus reducing the cost. The choice of beta versus gamma should ultimately depend upon the results of clinical studies and the task group was unable to come to a consensus regarding the optimum radionuclide.
Another controversial question was regarding the need for centering in a catheter-based system. The answer to this question would depend upon the choice of radionuclide and on the biological window of therapeutic efficacy without normal tissue toxicity. It appears, for example, that a minimum dose on the order of 8-16 Gy to a depth of 0.5 mm into the vessel wall is required to prevent restenosis. The maximum vessel tolerance dose is not well known but can be speculated to be on the order of 32 Gy to the surface of the vessel wall. These limits imply that dose uniformity within the target region must be within a factor of 2-4. The normal vessel wall thickness is on the order of 0.5 mm, and it is possible that all sections of the vessel wall need to be treated in order to prevent restenosis. Also, the diseased vessels could have thicker walls. Assuming a treatment wall thickness of 0.5 mm, even for a perfectly centered source, the dose variation to the various sections of the vessel wall ͑say, from radial distances of 1.5-2.0 mm͒ will be on the order of 50%-70%. Again, the answer to the question regarding the need for centering will have to wait for the completion of clinical investigations.
There are a number of other important questions that the task group could not resolve at this time. Some of them are ͑1͒ recommendations about the accuracy desired of the source calibration under standard conditions, ͑2͒ the accuracies of various calibration methods, ͑3͒ the expected accuracy of the dose delivered under clinical conditions, ͑4͒ a comparison of the clinical efficacy of catheter-based brachytherapy, radioactive stent implantation, and radioactive liquid balloons, ͑5͒ the consideration of the dose rate effects in the use of various modalities for intravascular brachytherapy, ͑6͒ consideration of the effects of contrast media, metallic stents, and plaque composition on the dose distribution produced by various forms of intravascular radiotherapy, and ͑7͒ recommended values for dosimetry parameters for each of the commercial systems. All of these issues should be addressed by scientific and clinical investigators in this field. The AAPM will continue to monitor scientific progress in this area and make further recommendations at an appropriate time in the near future. Closest to the point of reference. When referring to catheters, the reference point is the angiographer, who holds the proximal end of the catheter while the distal end is inserted into the patient. When referring to arteries, the reference point is the ostium, so a balloon catheter approaches a lesion from the proximal side. PTCA Percutaneous-through the skin, transluminal-through the lumen of a vessel, coronary pertaining to the heart, angioplasty repair of a blood vessel. Usually synonymous with balloon angioplasty. Pushability
The ability of the catheter shaft to transfer the force from the proximal end of the shaft to the distal tip so that the balloon or other device can be advanced through the vessel and across the stenosis. Radiopacity
The extent to which a catheter, wire, stent, or other device absorbs x rays, making it visible in an x-ray image. Radiopaque Impenetrable to an x ray or other forms of radiation. Rated burst pressure
The maximum pressure the manufacturer recommends for inflatingan angioplasty or stent delivery bal-loon, typically specified in atmo-spheres. The label recommends that the RBP should not be exceeded. RCA Right Coronary Artery. Serves the inferior wall of the left ventricle, parts of the right ventricle and interventricular septum, the right atrium, and may serve the left ventricular apex in some people.
Restenosis
Recurrence of a stenosis after a corrective procedure. 
